Literature DB >> 27605198

Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole.

Anne Mette Dybro1, Per Damkier2, Torsten Bloch Rasmussen3, Maja Hellfritzsch4.   

Abstract

A 47-year-old woman had been treated with high-dose simvastatin for several years. After systemic treatment with the antifungal agent itraconazole, she developed muscle pain and highly elevated levels of creatine kinase and myoglobin. Muscle biopsy was compatible with statin-associated rhabdomyolysis, probably caused by a drug-drug interaction between simvastatin and itraconazole. The patient made full recovery. Three commonly used statins-simvastatin, atorvastatin and lovastatin-are metabolised by the liver enzyme CYP3A4. Several potent inhibitors of this enzyme are known, for example, azole antifungal agents such as itraconazole and posaconazole. If antifungal treatment is indicated in a patient using a CYP3A4-metabolised statin, we recommend (1) topical administration of the antifungal agent if possible, (2) the use of a non-CYP3A4-inhibiting antifungal drug such as terbinafine or (3) temporary discontinuation of statin treatment. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27605198      PMCID: PMC5020717          DOI: 10.1136/bcr-2016-216457

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.

Authors:  Juhani Kahri; Miia Valkonen; Tom Bäcklund; Matti Vuoristo; Kari T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  2004-12-30       Impact factor: 2.953

Review 3.  Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Authors:  Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Journal:  Clin Pharmacol Ther       Date:  2006-12       Impact factor: 6.875

4.  Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.

Authors:  M Horn
Journal:  Arch Dermatol       Date:  1996-10

5.  Rhabdomyolysis-induced acute renal failure due to itraconazole and simvastatin association.

Authors:  Sébastien Roques; Maria Lytrivi; Daniel Rusu; Jacques Devriendt; David De Bels
Journal:  Drug Metabol Drug Interact       Date:  2011-04-18

6.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

Authors:  P J Neuvonen; T Kantola; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  1998-03       Impact factor: 6.875

7.  Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.

Authors:  Gopal Krishna; Lei Ma; Pratapa Prasad; Allen Moton; Monika Martinho; Edward O'Mara
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-12-19       Impact factor: 4.481

8.  Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.

Authors:  Jan L Maxa; Larry B Melton; Chris C Ogu; Michael N Sills; Alex Limanni
Journal:  Ann Pharmacother       Date:  2002-05       Impact factor: 3.154

9.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

10.  Simvastatin-fluconazole causing rhabdomyolysis.

Authors:  Aasma Shaukat; Mustafa Benekli; Georgirene D Vladutiu; James L Slack; Meir Wetzler; Maria R Baer
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

View more
  8 in total

1.  Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism.

Authors:  Sen Sun; Rong Wang; Jie Fan; Guoqing Zhang; Hai Zhang
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

2.  Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats.

Authors:  Yan Ren; Haifeng Li; Xing Liu
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

Review 3.  Chronic Pulmonary Aspergillosis: A Brief Review.

Authors:  Azmaeen Zarif; Adith Thomas; Alex Vayro
Journal:  Yale J Biol Med       Date:  2021-12-29

Review 4.  Acute rhabdomyolysis in hepatitis-associated aplastic anemia patient undergoing allogeneic hematopoietic stem-cell transplantation: case report and literature review.

Authors:  Yuzhu Li; Yilei Hong; Yingying Shen; Qi Liu; Ying Chen; Keding Shao; Yiping Shen; Baodong Ye; Dijiong Wu
Journal:  Eur J Med Res       Date:  2022-03-21       Impact factor: 2.175

5.  Detection of statin-induced rhabdomyolysis and muscular related adverse events through data mining technique.

Authors:  Patratorn Kunakorntham; Oraluck Pattanaprateep; Charungthai Dejthevaporn; Ratchainant Thammasudjarit; Ammarin Thakkinstian
Journal:  BMC Med Inform Decis Mak       Date:  2022-09-05       Impact factor: 3.298

6.  Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysis.

Authors:  Widya N Insani; Cate Whittlesea; Hassan Alwafi; Kenneth K C Man; Sarah Chapman; Li Wei
Journal:  PLoS One       Date:  2021-05-26       Impact factor: 3.240

Review 7.  The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach.

Authors:  Firas Maghrabi; David W Denning
Journal:  Curr Fungal Infect Rep       Date:  2017-11-13

Review 8.  Treatment of Dermatophytosis in Elderly, Children, and Pregnant Women.

Authors:  Subuhi Kaul; Savita Yadav; Sunil Dogra
Journal:  Indian Dermatol Online J       Date:  2017 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.